

### LIST OF TABLES

Table 1:	Natural biodegradable polymers in drug delivery.
Table 2:	Pharmaceutical applications of chitosan.
Table 3:	Pharmaceutical applications of PLGA formulations.
Table 4:	Implantable drug delivery systems for drugs and pharmaceuticals.
Table 5:	Various formulation factors affecting protein release kinetics and stability in biodegradable microspheres.
Table 6:	Pharmaceutical and biopharmaceutical considerations in the development of a microsphere product.
Table 7:	Formulation variables for PLGA formulations.
Table 8:	Formulation variables for PCL formulations.
Table 9:	Formulation variables for chitosan formulations.
Table 10:	Formulation variables for albumin (BSA) formulations.
Table 11:	Treatment schedule for BLM-loaded microspheres in mice bearing melanoma B16F1/fibrosarcoma tumour.
Table 12:	Treatment schedule for INS-loaded microspheres in diabetic rats.
Table 13:	Acute toxicity studies - Treatment schedule for BLM-loaded microspheres in Swiss mice.
Table 14:	Organ toxicity studied - Treatment schedule for BLM-loaded microspheres in Swiss mice.
Table 15:	Data for calibration curve of BLM in PBS pH 7.4
Table 16:	Data for calibration curve of INS in PBS pH 7.4
Table 17:	Effect of stabilizer type and concentration on microsphere size.
Table 18:	Effect of stirring speed on size of microspheres.
Table 19:	Influence of polymer concentration on microsphere size/entrapment efficiency
Table 20:	Influence of volume of internal phase on microsphere size/entrapment efficiency.
Table 21:	Influence of volume of external phase on microsphere size/entrapment efficiency.
Table 22:	Physicochemical characteristics of microspheres taken for further <i>in vitro</i> / <i>in vivo</i> investigations.
Table 23:	Effect of crosslinking density on <i>in vitro</i> release profile of BLM-loaded microspheres.
Table 24:	Stability kinetics of BLM-loaded microspheres.
Table 25:	Stability kinetics of INS-loaded microspheres.
Table 26:	Antitumour efficacy of BLM-loaded biodegradable microspheres in C57BL/6J mice bearing melanoma B16F1.
Table 27:	Antitumour efficacy of BLM-loaded biodegradable microspheres in Swiss mice bearing fibrosarcoma.
Table 28:	Antidiabetic potential of INS-loaded biodegradable microspheres.
Table 29:	Calibration curve data for BLM in mouse plasma.
Table 30:	Pharmacokinetic parameters of BLM-loaded biodegradable microspheres.
Table 31:	Calibration curve data for INS in rat plasma.
Table 32:	Pharmacokinetic parameters of INS-loaded biodegradable microspheres.
Table 33:	Acute toxicity testing of BLM-loaded biodegradable microspheres in Swiss mice.
Table 34:	Histopathological studies after treatment with BLM-loaded biodegradable microspheres.
Table 35:	Tissue disposition of free BLM in mice bearing Sarcoma-180 tumour.